Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
RESEARCH TOOLSreports
Milestone Pharmaceuticals (MIST) Stock Price & Analysis
421 Followers
MIST Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.12 - $3.86
Previous Close$1.33
Volume35.23K
Average Volume (3M)160.33K
Market Cap
$71.90M
Enterprise Value$34.93M
Total Cash (Recent Filing)$89.48M
Total Debt (Recent Filing)$52.51M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Aug 07, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding53,260,467
10 Day Avg. Volume93,634
30 Day Avg. Volume160,327
Standard Deviation0.29
R-Squared0.10
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.84
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$13.00Price Target Upside881.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Milestone Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Data SupportReal-world clinical data from Phase 3 trial supports CARDAMYST's potential in managing paroxysmal supraventricular tachycardia (PSVT) effectively.
Expansion OpportunityHighly underappreciated opportunity in PSVT with significant potential for expansion, in our view.
FDA ApprovalThe FDA accepted the New Drug Application for CARDAMYST, placing it on track for potential approval and launch in 2025.
Bears Say
Financial PerformanceThe price target has been adjusted to $9 vs prior $17.
Product LaunchPotential etripamil launch has been delayed to 2026 vs prior 2025.
Regulatory IssuesThe FDA requested clarification about time of data recorded for AEs in MIST's Phase 3 trials.
---
Ownership Overview
46.18%
Insiders
0.11% Mutual Funds
34.70% Other Institutional Investors
19.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MIST FAQ
What was Milestone Pharmaceuticals’s price range in the past 12 months?
Milestone Pharmaceuticals lowest stock price was $1.12 and its highest was $3.86 in the past 12 months.
What is Milestone Pharmaceuticals’s market cap?
Currently, no data Available
When is Milestone Pharmaceuticals’s upcoming earnings report date?
Milestone Pharmaceuticals’s upcoming earnings report date is Aug 07, 2024 which is in 34 days.
How were Milestone Pharmaceuticals’s earnings last quarter?
Milestone Pharmaceuticals released its earnings results on May 13, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.26 by $0.05.
Is Milestone Pharmaceuticals overvalued?
According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued.
Does Milestone Pharmaceuticals pay dividends?
Milestone Pharmaceuticals does not currently pay dividends.
What is Milestone Pharmaceuticals’s EPS estimate?
Milestone Pharmaceuticals’s EPS estimate is -$0.19.
How many shares outstanding does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 53,260,468 shares outstanding.
What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?
Milestone Pharmaceuticals reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.26. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Milestone Pharmaceuticals?
Among the largest hedge funds holding Milestone Pharmaceuticals’s share is RA Capital Management. It holds Milestone Pharmaceuticals’s shares valued at N/A.
---
Milestone Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (881.13% Upside)
$13.00 (881.13% Upside)
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.44%
12-Months-Change
Fundamentals
Return on Equity
-117.39%
Trailing 12-Months
Asset Growth
-13.57%
Trailing 12-Months
Company Description
Milestone Pharmaceuticals
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
---
MIST Stock 12 Month Forecast
Average Price Target
$13.00
▲(881.13% Upside)
Technical Analysis
Cassava Sciences
―
Arrowhead Pharmaceuticals
―
Kala Pharmaceuticals
―
Heron Therapeutics
―
Best Analysts Covering MIST
1 Year
1 Year Success Rate
3/21 ratings generated profit
1 Year Average Return
-30.70%
reiterated a buy rating 4 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -30.70% per trade.
---